Ferrini RL, Barrett-Connor E (1998) Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 147(8):750–754

CAS  PubMed  Google Scholar 

Mohr BA, Guay AT, O’Donnell AB, McKinlay JB (2005) Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts male ageing study. Clin Endocrinol (Oxf) 62(1):64–73

CAS  Google Scholar 

Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab 86(2):724–731

CAS  PubMed  Google Scholar 

Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW et al (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. J Clin Endocrinol Metab 93(7):2737–2745

CAS  PubMed  Google Scholar 

Corona G, Maseroli E, Rastrelli G, Francomano D, Aversa A, Hackett GI et al (2016) Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Minerva Endocrinol 41(2):196–210

PubMed  Google Scholar 

Handelsman DJ (2013) Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse. Med J Aust 199(8):548–551

PubMed  Google Scholar 

Layton JB, Kim Y, Alexander GC, Emery SL (2017) Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009–2013. JAMA 317(11):1159–1166

PubMed  PubMed Central  Google Scholar 

FDA Drug Safety Communication FDA cautions about using T products for low T due to aging requires labeling change to inform of possible increased risk of heart attack and stroke with use. US Food and Drug Administration website March 3rd , 2015 [Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due.

The Endocrine Society. The Risk of Cardiovascular Events in Men Receiving Testosterone Therapy. An Endocrine Society Statement February, 7th, 2014 [Available from: https://www.endocrine.org/~/media/endosociety/Files/Advocacy%20and%20Outreach/Position%20Statements/Other%20Statements/The%20Risk%20of%20Cardiovascular%20Events%20in%20Men%20Receiving%20Testosterone%20Therapy.pdf.

Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ et al (2016) Endocrine society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust 205(4):173–178

PubMed  Google Scholar 

Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S et al (2015) Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest 38(1):103–112

CAS  PubMed  Google Scholar 

Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH et al (2008) A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 93(3):666–673

CAS  PubMed  Google Scholar 

Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM et al (2018) Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103(5):1715–1744

PubMed  Google Scholar 

Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC et al (2021) European association of urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol 80(3):333–357

PubMed  Google Scholar 

Giagulli VA, Castellana M, Lisco G, Triggiani V (2020) Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology 8(6):1628–1641

PubMed  Google Scholar 

Lunenfeld B, Mskhalaya G, Zitzmann M, Corona G, Arver S, Kalinchenko S et al (2021) Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male 24(1):119–138

PubMed  Google Scholar 

Grossmann M, Matsumoto AM (2017) A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab 102(3):1067–1075

PubMed  PubMed Central  Google Scholar 

Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G et al (2020) European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European society of endocrinology. Andrology 8(5):970–987

PubMed  Google Scholar 

Corona G, Rastrelli G, Morelli A, Sarchielli E, Cipriani S, Vignozzi L et al (2020) Treatment of functional hypogonadism besides pharmacological substitution. World J Mens Health 38(3):256–270

PubMed  Google Scholar 

Salonia A, Rastrelli G, Hackett G, Seminara SB, Huhtaniemi IT, Rey RA et al (2019) Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers 5(1):38

PubMed  PubMed Central  Google Scholar 

Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi L et al (2007) Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 30(10):880–888

CAS  PubMed  Google Scholar 

Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD et al (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363(2):123–135

CAS  PubMed  Google Scholar 

Rastrelli G, Corona G, Tarocchi M, Mannucci E, Maggi M (2016) How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. J Endocrinol Invest 39(4):473–484

CAS  PubMed  Google Scholar 

Taylor AE, Keevil B, Huhtaniemi IT (2015) Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow. Eur J Endocrinol 173(2):D1-12

CAS  PubMed  Google Scholar 

Rosner W, Vesper H (2010) Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab 95(10):4542–4548

CAS  PubMed  Google Scholar 

Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y et al (2017) Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. J Clin Endocrinol Metab 102(4):1161–1173

PubMed  PubMed Central  Google Scholar 

Corona G, Torres LO, Maggi M (2020) Testosterone therapy: what we have learned from trials. J Sex Med 17(3):447–460

CAS  PubMed  Google Scholar 

Antonio L, Wu FC, O’Neill TW, Pye SR, Ahern TB, Laurent MR et al (2016) Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab 101(7):2647–2657

CAS  PubMed  Google Scholar 

Rastrelli G, O’Neill TW, Ahern T, Bártfai G, Casanueva FF, Forti G et al (2018) Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: prospective results from the EMAS. Clin Endocrinol (Oxf) 89(4):459–469

CAS  Google Scholar 

Fiers T, Wu F, Moghetti P, Vanderschueren D, Lapauw B, Kaufman JM (2018) Reassessing free-testosterone calculation by liquid chromatography-tandem mass spectrometry direct equilibrium dialysis. J Clin Endocrinol Metab 103(6):2167–2174

PubMed  Google Scholar 

Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84(10):3666–3672

CAS  PubMed  Google Scholar 

Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD et al (2010) Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. J Clin Endocrinol Metab 95(4):1810–1818

CAS  PubMed  Google Scholar 

Oduwole OO, Peltoketo H, Huhtaniemi IT (2018) Role of follicle-stimulating hormone in spermatogenesis. Front Endocrinol (Lausanne) 9:763

Google Scholar 

Dalvi M, Walker BR, Strachan MW, Zammitt NN, Gibb FW (2016) The prevalence of structural pituitary abnormalities by MRI scanning in men presenting with isolated hypogonadotrophic hypogonadism. Clin Endocrinol (Oxf) 84(6):858–861

CAS  Google Scholar 

Cipriani S, Todisco T, Ghiandai N, Vignozzi L, Corona G, Maggi M et al (2021) Biochemical predictors of structural hypothalamus-pituitary abnormalities detected by magnetic resonance imaging in men with secondary hypogonadism. J Endocrinol Invest 44(12):2785–2797

CAS  PubMed  PubMed Central  Google Scholar 

Das G, Surya A, Okosieme O, Vali A, Tennant BP, Geen J et al (2019) Pituitary imaging by MRI and its correlation with biochemical parameters in the evaluation of men with hypogonadotropic hypogonadism. Endocr Pract 25(9):926–934

PubMed  Google Scholar 

Eendebak R, Ahern T, Swiecicka A, Pye SR, O’Neill TW, Bartfai G et al (2018) Elevated luteinizing hormone despite normal testosterone levels in older men-natural history, risk factors and clinical features. Clin Endocrinol (Oxf) 88(3):479–490

CAS  Google Scholar 

Corona G, Rastrelli G, Dicuio M, Concetti S, Minnetti M, Pivonello R et al (2021) Subclinical male hypogonadism. Minerva Endocrinol (Torino) 46(3):252–261

Google Scholar 

Corona G, Maseroli E, Rastrelli G, Sforza A, Forti G, Mannucci E et al (2014) Characteristics of compensated hypogonadism in patients with sexual dysfunction. J Sex Med 11(7):1823–1834

CAS  PubMed  Google Scholar 

Veldhuis JD, Bondar OP, Dyer RB, Trushin SA, Klee EW, Singh RJ et al (2014) Immunological and mass spectrometric assays of SHBG: consistent and inconsistent metabolic associations in healthy men. J Clin Endocrinol Metab 99(1):184–193

CAS  PubMed  Google Scholar 

Coluzzi F, Billeci D, Maggi M, Corona G (2018) Testosterone deficiency in non-cancer opioid-treated patients. J Endocrinol Invest 41(12):1377–1388

CAS  PubMed  PubMed Central  Google Scholar 

Rastrelli G, Maggi M, Corona G (2018) Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol 11(4):439–458

CAS  PubMed  Google Scholar 

Corona G, Maseroli E, Maggi M (2014) Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother 15(13):1903–1926

CAS  PubMed  Google Scholar 

Awouters M, Vanderschueren D, Antonio L (2020) Aromatase inhibitors and selective estrogen receptor modulators: unconventional therapies for functional hypogonadism? Andrology 8(6):1590–1597

CAS  PubMed  Google Scholar 

Corona G, Baldi E, Maggi M (2011) Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest 34(3):232–243

CAS  PubMed  Google Scholar